Determining the best length of antibiotic treatment for kidney transplant infections
Official title: Planning an antibiotic duration trial for acute graft pyelonephritis after kidney transplantation
Funded at Univ of North Carolina Chapel Hill · NIH-10690286 · Data updated 2026-11-12
This study is looking at how long kidney transplant patients should take antibiotics for a common infection called acute graft pyelonephritis, to find the shortest time that still keeps them safe and healthy.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project start | August 2, 2023 |
| Project end | July 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $226,219 |
| NIH project number | 1R34AI170386-01A1 |
| Project ID | NIH-10690286 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals who have recently undergone kidney transplantation and are experiencing acute graft pyelonephritis.
✕Less likely to help
Patients who are not kidney transplant recipients or those who do not have acute graft pyelonephritis may not benefit from this research.
What this research studies
This research aims to find the optimal duration of antibiotic treatment for acute graft pyelonephritis, a common infection that can occur after kidney transplantation. The study will involve a multi-center, randomized trial where patients will be assigned to different treatment durations ranging from 7 to 21 days. By comparing these durations, the researchers hope to identify the shortest effective treatment that minimizes side effects and costs while maintaining patient safety. This approach is designed to improve care for kidney transplant recipients who are at risk for serious infections.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer antibiotic treatment protocols for kidney transplant recipients, reducing the risk of complications.
How similar studies have gone: Previous research has shown that optimizing antibiotic treatment durations can lead to better patient outcomes, suggesting that this approach has potential for success.
Where this research is happening
-
Univ of North Carolina Chapel Hill
Chapel Hill, United States Active
Researchers
- Principal investigator: Van Duin, David — Univ of North Carolina Chapel Hill
- Study coordinator: Van Duin, David
Related research
Other NIH-funded projects on the same topics.
-
Strategies for HIV-to-HIV kidney transplants to increase organ donations
This project looks at making HIV-to-HIV kidney transplantation more common to help people with HIV get transplants faster by boosting organ donation and changing practice.
-
Biomarker-guided Immunosuppression in Kidney Transplant Patients
A multicenter study in kidney transplant recipients is testing whether a biomarker score from HLA-DR/DQ can guide changes in immunosuppression to reduce rejection risk and drug toxicity.
-
Helping the immune system accept a donated kidney in patients without prior sensitization
This project will try giving specially treated donor B cells alongside immune-sparing medicines to teach the immune systems of kidney transplant patients without prior antibodies to accept the new kidney.
-
Lowering donor-specific antibodies in sensitized kidney transplant patients
This project works to reduce harmful donor-specific antibodies in people who are sensitized and need a kidney transplant so their new organ lasts longer.
-
Reducing geographic disparities in kidney transplant access with AI and operations research
Aiming to use AI and operations research to make kidney transplant access more fair across different regions in the U.S.
-
Centralized patient coaching to boost live donor kidney transplantation
A US-wide program trains patients, caregivers, and their networks with coaching to help them pursue living donor kidney transplantation.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.